Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886384 | 0.95 | TLR8 (0.48) | TLR7TLR8FGFR1SRCCXCL8 | |
| SCHEMBL10025467 | 0.95 | TLR8 (0.48) | TLR7TLR8FGFR1SRCCXCL8 | |
| SCHEMBL23102167 | 0.92 | TLR8 (0.47) | TLR7TLR8FGFR1SRCCXCL8 | |
| SCHEMBL3503268 | 0.89 | ACSS2 (0.47) | TLR8FGFR1SRCCXCL8NOD1 | |
| SCHEMBL10025566 | 0.85 | TLR7 (0.40) | TLR7TLR8FGFR1SRCCXCL8 | |
| SCHEMBL3498283 | 0.84 | TLR8 (0.49) | TLR8CXCR4 | |
| SCHEMBL3574672 | 0.84 | HRH3 (0.52) | TLR7HRH3 | |
| SCHEMBL3498559 | 0.82 | NPC1 (0.45) | FGFR1SRCKMT2AHRH3 | |
| SCHEMBL14447549 | 0.78 | TLR8 (0.71) | TLR7TLR8CXCR4 | |
| SCHEMBL12598790 | 0.77 | BACE1 (0.54) | TLR8CXCL8NOD1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20050165007-A1 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050124638-A1 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2004050035-A2 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165007-A1 | Benzimidazoles and analogs thereof as antivirals | ZC3HAV1, NXF1, ZC3HAV1L | TLR7 3231/4885TLR8 4042/4885FGFR1 4269/4885 |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | TLR7 3231/4885TLR8 4042/4885FGFR1 4269/4885 |
| US-20050124638-A1 | Benzimidazoles and analogs thereof as antivirals | ZC3HAV1, NXF1, ZC3HAV1L | TLR7 3231/4885TLR8 4042/4885FGFR1 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.